Envista (NVST) Q4 2025 earnings review
Strong Finish: Double-Digit Growth & Profitability Inflection
Envista capped a recovery year with accelerating momentum. Q4 core sales growth hit 10.8%, a significant acceleration from 9.4% in Q3 and 0.2% in Q1. Crucially, the growth was broad-based—both Equipment & Consumables (+10.7%) and Specialty Products (+10.9%) posted double-digit gains. Profitability followed suit, with Adjusted EBITDA rising 22% YoY and EPS surging 58%. The Spark aligner business achieving profitability in H2 2025 (as promised) marks a pivotal transition from investment drag to margin contributor. However, FY26 guidance suggests a significant moderation (2-4% growth), implying Q4's velocity benefited from temporary tailwinds.
🐂 Bull Case
The Spark business has officially crossed the threshold into profitability (implied by Segment margin expansion and prior guidance). This removes a multi-year margin drag and positions the fastest-growing product line as an earnings driver for FY26.
Unlike prior quarters dependent on specific segments, Q4 saw synchronized double-digit core growth in both 'Specialty Products' and 'Equipment & Consumables.' All major geographies delivered positive growth.
🐻 Bear Case
Despite exiting Q4 with 10.8% core growth, management guided FY26 core growth to just 2-4%. This suggests significant one-off benefits in Q4 (likely the tail-end of Spark deferral recognition or year-end budget flushes) that will not repeat.
While executed well in 2025, the dental market remains sensitive to consumer discretionary spending. The reliance on continued R&D investment to drive growth against a backdrop of potential tariff volatility remains a risk factor.
⚖️ Verdict: 🟢
Bullish. Execution was flawless in Q4, delivering the promised acceleration and profitability improvements. While the conservative FY26 guide warrants caution against extrapolating Q4's 10% growth linearly, the fundamental turnaround from the 'transition year' of 2024 is now undeniably confirmed.
Key Themes
Spark & Specialty Margin Expansion
Specialty Products & Technologies (which includes Spark) saw Adjusted Operating Margins expand to 16.2% in Q4 from 11.5% a year ago. This verifies the narrative that Spark volume scaling is now accretive rather than dilutive. With unit costs down (noted in prior calls) and volume up, this segment is the primary engine for the 22% total EBITDA growth.
Equipment & Consumables Resurgence
Often the laggard, Equipment & Consumables posted 10.7% core growth in Q4. This segment has been volatile (1.7% in Q1), but the strong finish suggests robust demand for consumables and a potential stabilization in the equipment capex cycle, or successful market share gains in implants/imaging.
Guidance Conservatism or Reality Check?
The FY26 outlook projects Core Sales Growth of 2-4%. This is a stark contrast to the 9.4% (Q3) and 10.8% (Q4) realized recently. Investors must determine if H2 2025 was inflated by accounting mechanics (Spark revenue deferral recognition mentioned in Q3) or if the underlying market is expected to slow materially.
Capital Return Activity
Envista repurchased $24M in shares in Q4 and $166M for the full year. While positive, the pace slowed in Q4 compared to Q3 ($40M) and Q2 ($82M). Remaining capacity is $84M, suggesting a potential need for a new authorization soon if buybacks are to continue as a primary support.
Innovation Investment Payoff
Management cited a 'double-digit increase in R&D investment' as a driver for 2025's success. This spending is flowing through to the P&L (R&D expense $32.1M in Q4 vs $26.7M prior year), but revenue growth is outpacing this expense growth, proving the ROI of these investments.
Other KPIs
Accelerating. Up 22% YoY. Margin expanded 90bps to 14.8%. This demonstrates strong operating leverage as volume returned.
Beat. Came in above the raised guidance range ($1.10-$1.15 provided in Q3). Represents 63% YoY growth from the depressed levels of FY24.
Decelerating. Down from $303M in FY24. While conversion remains strong (~114%), cash flow was impacted by working capital needs to support higher growth rates and inventory builds.
Guidance
Decelerating. Implies a significant slowdown from the 10.8% exit rate in Q4 25. Likely reflects the normalization of Spark revenue recognition tailwinds and a cautious view on the broader dental macro.
Stable. Suggests continued margin expansion (assuming revenue grows at midpoint 3%, EBITDA growing ~10% implies operating leverage), but at a slower pace than the 20%+ growth seen in 25Q4.
Accelerating. Implies ~13-22% YoY growth off the $1.19 FY25 base. Driven by operational improvements and share count reductions.
Key Questions
Q4 Growth vs FY26 Guide Disconnect
Core growth was nearly 11% in Q4, yet you are guiding 2-4% for FY26. How much of Q4's strength was one-time (Spark deferral/Budget flush) versus sustainable demand?
China VBP 2.0 Exposure
Previous calls mentioned potential Implant VBP 2.0 in China. Is the impact of this included in the low-end of the 2-4% guidance, and what is the expected timing?
Margin Runway
With Spark now profitable, what is the next major lever for EBITDA margin expansion to reach peer levels, given that tariff headwinds persist?
Capital Allocation Priorities
With only $84M remaining in the repurchase authorization and cash flow conversion strong, should we expect a new authorization or a shift toward M&A in 2026?